Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2)

J Virol. 2000 Oct;74(20):9771-5. doi: 10.1128/jvi.74.20.9771-9775.2000.

Abstract

Postexposure prophylaxis (PEP) after intravaginal exposure to human immunodeficiency virus (HIV) was investigated using the HIV type 2 (HIV-2)/pig-tailed macaque transmission model. PEP for 28 days with the reverse transcriptase inhibitor (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA; tenofovir) was initiated 12 to 72 h following HIV-2 exposure. Systemic infection was not evident in the 12- and 36-h groups, as defined by plasma viremia, cell-associated provirus, antibody responses, and lymph node virus. Breakthrough infection in the 72-h group was detected at week 16 post-virus exposure. These results demonstrate for the first time using a vaginal transmission model that early intervention after high-risk sexual exposures may prevent infection.

MeSH terms

  • Acquired Immunodeficiency Syndrome / prevention & control*
  • Acquired Immunodeficiency Syndrome / transmission
  • Adenine / analogs & derivatives*
  • Adenine / therapeutic use
  • Animals
  • Anti-HIV Agents / therapeutic use*
  • Female
  • HIV-2 / isolation & purification*
  • Humans
  • Macaca nemestrina
  • Organophosphonates*
  • Organophosphorus Compounds / therapeutic use*
  • RNA, Viral / analysis
  • Tenofovir
  • Vagina / virology*

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Organophosphorus Compounds
  • RNA, Viral
  • Tenofovir
  • Adenine